Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 39%
Buy 55%
Hold 3%
Sell 3%
Strong Sell 0%

Bulls say

Insmed Inc is positioned for strong growth due to its innovative product pipeline and expanding market presence. The company has reiterated its full-year 2025 global revenue guidance for its first commercial product, ARIKAYCE, in the range of $405 million to $425 million, with projections for significant market expansion supported by a large volume of diagnosed patients and high misdiagnosis rates. Additionally, the anticipated launch of Brensocatib, which has generated considerable physician interest and is expected to capture a substantial market opportunity in bronchiectasis, further enhances the company's financial outlook.

Bears say

Insmed Inc. faces multiple risks that contribute to a negative outlook on its stock, including the potential for unexpected safety events or inadequate efficacy of its drug pipeline, which could hinder clinical trials and regulatory approval processes. The company reported substantial financial losses, with a net loss of $235.5 million for 4Q24 and a total of $913.8 million for FY24, raising concerns over its ability to sustain operations and fulfill debt obligations amid significant research and development expenses. Furthermore, challenges in commercialization, alongside possible delays and setbacks in product launches, may further diminish revenue generation prospects, reinforcing the negative sentiment.

Insmed (INSM) has been analyzed by 31 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 55% recommend Buy, 3% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 31 analysts, Insmed (INSM) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.